Progenics Pharmaceuticals, Inc. announced the appointment of Asha Das, M.D. to the newly created role of Chief Medical Officer. Dr. Das brings 13 years of drug development experience, including leading activities related to the approval and launch of Avastin in multiple indications at Genentech, as well as a decade of clinical practice and academic expertise in neurology and neuro-oncology. Dr. Das most recently served as Tocagen’s Chief Medical Officer, where she led the development of the company’s cancer-selective gene therapy platform. From April 2008 to April 2015, Dr. Das served at Genentech, in positions of increasing responsibility, initially as Associate Medical Director and ultimately as Group Medical Director. She was responsible for leading activities related to the approval and launch of Avastin in recurrent glioblastoma, expansion into platinum-resistant ovarian cancer and metastatic cervical cancer as well as clinical activities related to TECENTRIQ. From 2005 to 2008, Dr. Das served as Associate Medical Director at Eisai Inc., a pharmaceutical company, where she focused on clinical activities related to the oncology therapeutics HALAVEN and LENVIMA. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center.